OpenAI has reportedly met with officials from the Food and Drug Administration to discuss how AI could speed up drug ...

The Food and Drug Administration says that a prominent medical contrarian and critic of the drug industry will head its ...

High-ranking OpenAI employees have met with the FDA multiple times in recent weeks to discuss AI and a project called cderGPT ...

OpenAI and the U.S. Food and Drug Administration have been meeting to discuss the health regulator's use of AI, technology ...

The U.S. Food and Drug Administration said on Thursday all its centers will deploy artificial intelligence internally ...

The Food and Drug Administration on Thursday announced an aggressive agency-wide Artificial intelligence adoption timeline ...

The FDA is warning the public about a drug rising in popularity commonly referred to as as "gas station heroin." ...

The U.S. Food and Drug Administration said Tuesday it will expand its use of unannounced inspections at foreign manufacturing ...

The FDA is urging the food industry to phase out artificial food dyes, including Red Dye No. 3, citing potential health risks ...

Accelerated approval was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS-mutated recurrent low-grade serous ovarian cancer, the company said.

FDA's plan to deploy an AI tool to assist with scientific review process raises questions about transparency and risks.

Food and Drug Administration Commissioner Marty Makary, M.D., spoke about the need to shorten the length of the drug approval ...